Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 4 1Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Dermatologic 1CNS 1

Conditions

Glioma 2Thyroid Neoplasms 1Oligodendroglioma 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Neurocytoma 1Neuroblastoma 1Melanoma 1Lung Neoplasms 1Histiocytosis, Langerhans-Cell 1Glioblastoma 1Ganglioneuroma 1Ganglioglioma 1Carcinoma, Non-Small-Cell Lung 1Astrocytoma 1Advanced Thyroid Cancer Patients Who Received Target Therapy 1

Interventions

Pemetrexed 10Cisplatin 9Erlotinib Hydrochloride 8Carboplatin 7icotinib 5Gefitinib 5Docetaxel 5endostar protein 3Zoledronic Acid 3Radiotherapy 3Paclitaxel 3Gemcitabine 3Endostatins 3Afatinib 3tislelizumab 2pembrolizumab 2osimertinib 2lorlatinib 2flurbiprofen axetil 2dexamethasone 21-phosphate 2atezolizumab 2Vinorelbine 2Surgical Procedures, Operative 2Saline Solution 2Nivolumab 2Drug Therapy 2Dexamethasone 2Chemoradiotherapy 2trametinib 1spartalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Carcinoma, Non-Small-Cell Lung × dabrafenib × Clear all
NCT03340506 2026-04-20

Dabrafenib and/or Trametinib Rollover Study

Novartis

Phase 4 Recruiting
100 enrolled
CNSDermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Glioma, Lung Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡